Variant Summary
- HGVS
- —
- Variant Type(s)
- —
- Evidence Items
- 9
Evidence Level Distribution
Level B: 9
Evidence Items
Showing CIViC evidence rows where gene = EGFR and variant = Overexpression.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Predictive | Does Not Support | Sensitivity/Response | Head And Neck Squamous Cell Carcinoma | Cetuximab | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 4 |
| B | Prognostic | Supports | Poor Outcome | Brain Glioblastoma Multiforme | 3 | |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 3 |
| B | Prognostic | Supports | Poor Outcome | Head And Neck Squamous Cell Carcinoma | 3 | |
| B | Predictive | Does Not Support | Sensitivity/Response | Esophagus Squamous Cell Carcinoma | Nimotuzumab | 3 |
| B | Prognostic | Supports | Poor Outcome | Esophagus Squamous Cell Carcinoma | 3 | |
| B | Predictive | Does Not Support | Sensitivity/Response | Head And Neck Squamous Cell Carcinoma | Docetaxel,Cetuximab | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | 3 |